Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound

This article was originally published in The Pink Sheet Daily

Executive Summary

Oral Janus associated kinase inhibitor '424 may prove superior to currently approved anti-TNF agents and Roche’s IL-6 inhibitor Actemra for RA, Incyte CEO says.

You may also be interested in...



Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.

Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.

Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis

Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel